KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) Equity Average (2018 - 2025)

Castle Biosciences' Equity Average history spans 7 years, with the latest figure at $469.0 million for Q4 2025.

  • For Q4 2025, Equity Average rose 4.57% year-over-year to $469.0 million; the TTM value through Dec 2025 reached $469.0 million, up 4.57%, while the annual FY2025 figure was $463.4 million, 9.4% up from the prior year.
  • Equity Average for Q4 2025 was $469.0 million at Castle Biosciences, up from $461.2 million in the prior quarter.
  • Across five years, Equity Average topped out at $469.0 million in Q4 2025 and bottomed at $382.0 million in Q2 2023.
  • The 5-year median for Equity Average is $413.5 million (2021), against an average of $417.9 million.
  • The largest annual shift saw Equity Average skyrocketed 382.12% in 2021 before it dropped 8.23% in 2023.
  • A 5-year view of Equity Average shows it stood at $411.7 million in 2021, then decreased by 1.57% to $405.3 million in 2022, then decreased by 4.14% to $388.5 million in 2023, then rose by 15.42% to $448.4 million in 2024, then increased by 4.57% to $469.0 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Equity Average are $469.0 million (Q4 2025), $461.2 million (Q3 2025), and $447.8 million (Q2 2025).